These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

438 related articles for article (PubMed ID: 2433542)

  • 21. Comparison between the positive inotropic effects of enoximone, a cardiac phosphodiesterase III inhibitor, and dobutamine in patients with moderate to severe congestive heart failure. A study using the end-systolic pressure-volume relationship method.
    Installe E; De Coster P; Gonzalez M; Brichant C; Lessire H; Cauwe F
    Eur Heart J; 1991 Sep; 12(9):985-93. PubMed ID: 1834466
    [TBL] [Abstract][Full Text] [Related]  

  • 22. [New inotropic agents in the treatment of congestive heart failure].
    Freitas M
    Rev Port Cardiol; 1993 Nov; 12 Suppl 4():19-28, 7-8. PubMed ID: 7904458
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [New inotropic agents in the treatment of refractory congestive heart failure].
    Hertzeanu H; Pines A
    Harefuah; 1988 Mar; 114(6):290-3. PubMed ID: 3286406
    [No Abstract]   [Full Text] [Related]  

  • 24. Levosimendan in patients with low-output heart failure: lessons from the LIDO trial.
    Follath F
    Ital Heart J; 2003 May; 4 Suppl 2():34S-38S. PubMed ID: 14635368
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Hemodynamic effects of enoximone--comparative studies of heart surgery patients].
    Boldt J; Hempelmann G
    Z Kardiol; 1991; 80 Suppl 4():41-6. PubMed ID: 1833896
    [TBL] [Abstract][Full Text] [Related]  

  • 26. [Rational and irrational approach to the inotropic agent therapy of heart failure].
    Colombo F; Libretti A
    Clin Ter; 1988 Sep; 126(6):421-6. PubMed ID: 2974404
    [No Abstract]   [Full Text] [Related]  

  • 27. Non-glycoside, non-catecholamine inotropic agents in the treatment of congestive heart failure.
    Tommaso CL
    Am J Med; 1986 Feb; 80(2B):36-9. PubMed ID: 3004210
    [No Abstract]   [Full Text] [Related]  

  • 28. Reassessment of dobutamine, dopamine, and milrinone in the management of acute heart failure syndromes.
    Bayram M; De Luca L; Massie MB; Gheorghiade M
    Am J Cardiol; 2005 Sep; 96(6A):47G-58G. PubMed ID: 16181823
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Is inotropic therapy appropriate for patients with chronic congestive heart failure? Or is the digitalis leaf withering?
    Uretsky BF
    Postgrad Med J; 1986 Jun; 62(728):585-92. PubMed ID: 2946034
    [TBL] [Abstract][Full Text] [Related]  

  • 30. New positive inotropic drugs for the treatment of congestive heart failure.
    Sonnenblick EH; Mancini DM; LeJemtel TH
    Am J Cardiol; 1985 Jan; 55(2):41A-44A. PubMed ID: 2981465
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Levosimendan: a novel inotropic agent for treatment of acute, decompensated heart failure.
    Earl GL; Fitzpatrick JT
    Ann Pharmacother; 2005 Nov; 39(11):1888-96. PubMed ID: 16219899
    [TBL] [Abstract][Full Text] [Related]  

  • 32. New inotropic-vasodilating drugs in acute and chronic heart failure.
    Goenen MJ
    Ann Med Interne (Paris); 1986; 137(3):229-34. PubMed ID: 3767191
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of milrinone on left ventricular performance and myocardial contractility in patients with severe heart failure.
    Sonnenblick EH; Grose R; Strain J; Zelcer AA; LeJemtel TH
    Circulation; 1986 Mar; 73(3 Pt 2):III162-7. PubMed ID: 3510772
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Inotropic drugs for treatment of the failing heart.
    Maskin CS; Le Jemtel TH; Sonnenblick EH
    Cardiovasc Clin; 1984; 14(3):1-17. PubMed ID: 6327040
    [No Abstract]   [Full Text] [Related]  

  • 35. Inotropes in the management of acute heart failure.
    Petersen JW; Felker GM
    Crit Care Med; 2008 Jan; 36(1 Suppl):S106-11. PubMed ID: 18158469
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Can pharmacological therapy influence the mortality of chronic congestive heart failure?
    Widimský J
    Cor Vasa; 1992; 34(1):15-30. PubMed ID: 1288941
    [TBL] [Abstract][Full Text] [Related]  

  • 37. General overview and update of positive inotropic therapy.
    Leier CV
    Am J Med; 1986 Oct; 81(4C):40-5. PubMed ID: 2946223
    [TBL] [Abstract][Full Text] [Related]  

  • 38. [Vasodilatation and positive inotropic effect of the phosphodiesterase inhibitor enoximone].
    Holubarsch C; Hasenfuss G; Thierfelder L; Heiss HW; Just H
    Z Kardiol; 1991; 80 Suppl 4():35-40. PubMed ID: 1833895
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Intermittent inotropic infusions combined with prophylactic oral amiodarone for patients with decompensated end-stage heart failure.
    Drakos SG; Kanakakis JV; Nanas S; Bonios M; Kaldara E; Katsaros F; Pantsios C; Nanas JN
    J Cardiovasc Pharmacol; 2009 Feb; 53(2):157-61. PubMed ID: 19188832
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Inotropic therapy for heart failure: an evidence-based approach.
    Felker GM; O'Connor CM
    Am Heart J; 2001 Sep; 142(3):393-401. PubMed ID: 11526351
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.